l e t t e r S Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor-encoding genes SF3B1, U2AF1, and SRSF2 that confer an alteration of function [1] [2] [3] [4] [5] [6] . Cancer cells bearing these mutations are preferentially dependent on wild-type (WT) spliceosome function [7] [8] [9] [10] [11] , but clinically relevant means to therapeutically target the spliceosome do not currently exist. Here we describe an orally available modulator of the SF3b complex, H3B-8800, which potently and preferentially kills spliceosome-mutant epithelial and hematologic tumor cells. These killing effects of H3B-8800 are due to its direct interaction with the SF3b complex, as evidenced by loss of H3B-8800 activity in drugresistant cells bearing mutations in genes encoding SF3b components. Although H3B-8800 modulates WT and mutant spliceosome activity, the preferential killing of spliceosomemutant cells is due to retention of short, GC-rich introns, which are enriched for genes encoding spliceosome components. These data demonstrate the therapeutic potential of splicing modulation in spliceosome-mutant cancers.
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Heterozygous hotspot mutations in the genes encoding the RNA splicing factors splicing factor 3B subunit 1 (SF3B1), U2 small nuclear RNA auxiliary factor 1 (U2AF1), and serine and arginine rich splicing factor 2 (SRSF2) are among the most common mutations in patients with myelodysplastic syndromes (MDS) 1, 12 , chronic myelomonocytic leukemia (CMML) 1 , and chronic lymphocytic leukemia (CLL) 2 , and they also occur in a number of solid tumors (including breast 6 , lung 4 , uveal melanoma 3 , and pancreatic carcinomas 5 ). RNA splicing is the process through which introns are removed from precursor mRNAs (pre-mRNAs) to produce mature mRNAs 13, 14 . Introns typically feature a short consensus sequence at the 5′ splice site and three elements, namely the branchpoint sequence (BPS), a polypyrimidine tract (Py-tract), and an AG dinucleotide at the intron-exon junction, at the 3′ splice site. Recent work has demonstrated that mutations in the genes encoding SF3B1, U2AF1, and SRSF2 alter their functions in a manner distinct from that underlying loss of function [15] [16] [17] . Specifically, SF3B1 mutations induce cryptic 3′ splice site selection through reduction of branchpoint fidelity 17, 18 . In contrast, mutations in SRSF2 alter its RNA-binding preferences in a sequence-specific manner, thereby changing the efficiency of exon inclusion 15, 19 . Although the mechanisms through which these effects in RNA splicing promote cancer are still being investigated, several groups have demonstrated that cells with a mutant splicing factor are exquisitely sensitive to genetic or pharmacologic perturbation of splicing [7] [8] [9] [10] [11] . However, the splice modulators used in these preclinical studies were not optimized to induce preferential lethality in spliceosome-mutant cells, are not orally bioavailable, and are not progressing for clinical development 11, 20 .
To address these issues, we specifically set out to identify orally bioavailable small molecules with preferential cytotoxicity in spliceosome-mutant cells. Through an iterative medicinal chemistry effort starting from a scaffold based on pladienolide, we identified the small molecule H3B-8800, which potently competed with pladienolide for binding to SF3b complexes containing either WT or mutant SF3B1 ( Fig. 1a and Supplementary Fig. 1a) . The competitive binding between pladienolide and H3B-8800 was similar for SF3b complexes containing WT SF3B1 and those containing each of eight different cancer-associated SF3B1 mutants (Fig. 1b,  Supplementary Fig. 1b , and Supplementary Table 1 ). In accordance with these binding data and similarly to E7107, a pladienolide analog 20 , H3B-8800 demonstrated dose-dependent inhibition of both canonical splicing and aberrant splicing induced by mutant SF3B1 in in vitro assays of biochemical splicing (Fig. 1c,d and Supplementary Fig. 1c,d ). These results indicate that H3B-8800 potently binds and inhibits splicing catalysis by both WT SF3B1 and its mutant forms in vitro.
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers using the Ad2-ZDHHC16 pre-mRNA substrate, in which the original Ad2 intron was substituted with intron 9 of ZDHHC16, in an in vitro splicing assay using nuclear extracts from 293FT cells overexpressing SF3B1 K700E and treated with increasing concentrations of H3B-8800. The y axis represents the percent response relative to the DMSO control (0% l e t t e r S nature medicine VOLUME 24 | NUMBER 4 | APRIL 2018
endogenous locus (Supplementary Fig. 2 ). In addition, H3B-8800, but not E7107, demonstrated preferential killing of K562 cells bearing SF3B1 K700E as compared to their isogenic SF3B1 WT counterparts (Supplementary Fig. 1f ).
To verify the selectivity of H3B-8800 for the SF3b complex, we tested the activity of H3B-8800 in HCT116 cells with acquired resistance to pladienolides 21 due to mutations in SF3B1 or PHF5A, which encode components of the SF3b complex involved in branchpoint recognition 22 . SF3B1-R1074H or PHF5A-Y36C mutants conferred resistance to H3B-8800, whereas resistance to bortezomib, a compound whose mechanistic effects are not splicing dependent, was not observed in cells with these mutants (Fig. 1h and Supplementary  Fig. 1g ). These data indicate the selectivity of H3B-8800 for the SF3b complex and suggest that H3B-8800 may function through interfering with the interaction between the SF3b complex and the branchpoint. To test this hypothesis, we incubated nuclear extract from HCT116 parental cells with H3B-8800, ATP, and a 32 P-2′-O-methyl oligonucleotide complementary to the U2 small nuclear RNA (snRNA) branchpoint binding region (BBR). H3B-8800 inhibited ATP-dependent 17S U2 small nuclear ribonucleoprotein (snRNP) complex formation ( Fig. 1i) , providing evidence that H3B-8800 abolishes precatalytic spliceosome assembly, as was previously proposed for E7107 (ref. 23 ). This inhibition was not observed for nuclear extracts from the two H3B-8800-resistant cell lines (Fig. 1i) , suggesting that H3B-8800 modulates splicing through interfering with the interaction between the SF3b complex and the branchpoint region.
We next tested the antitumor effects of H3B-8800 in vivo in NOD-SCID interleukin-2 receptor gamma (IL2Rγ) null (NSG) mice bearing xenografts of isogenic K562 cells with SF3B1 WT or SF3B1 K700E (p.K700E was introduced through genetic modification of the endogenous SF3B1 locus). Oral administration of 2 or 4 mg H3B-8800 per kg body weight (mg/kg) daily slowed the growth of xenografts with SF3B1 K700E (P < 0.003, two-way ANOVA followed by Dunnett's multiple comparison test) but had no effect on SF3B1 WT xenografts. Although a dose of 8 mg/kg did slow the growth of SF3B1 WT tumors, it completely abrogated growth of SF3B1 K700E tumors (P < 0.003; Fig. 2a,b) . H3B-8800 similarly demonstrated significant antitumor activity against xenografts of human HNT-34 acute myeloid leukemia (AML) cells bearing the endogenous mutation encoding SF3B1-K700E (Supplementary Fig. 3a ). H3B-8800 reached similar concentrations in plasma as well as in tumors of mice harboring SF3B1 WT or SF3B1 K700E xenografts, and H3B-8800 modulated both canonical and aberrant splicing in a dose-dependent manner ( Fig. 2c and Supplementary Fig. 4 ). Splicing modulation was observed as early as 1 h following treatment, and splicing returned to pretreatment levels within 24 h following treatment, in accordance with the H3B-8800's pharmacokinetic profile (Fig. 2c) .
H3B-8800 treatment resulted in antileukemic efficacy and splicing modulation in mice bearing AML patient-derived xenografts (PDXs) with a mutation in SF3B1 but had little effect in mice bearing SF3B1 WT AML PDXs. In this experiment, NSGS mice (NSG mice with transgenic expression of human granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, and SCF) were engrafted with AML cells from a patient with AML harboring SF3B1 K700E , NRAS A59T , and inv(3)(q21q26.2) or from a patient with AML harboring variations in KRAS, WT1, and MLL1 but lacking any mutations in spliceosomerelated genes (Supplementary Table 2 ). In mice engrafted with the SF3B1 K700E PDX, 10 d of H3B-8800 treatment significantly reduced leukemic burden relative to that in vehicle-treated mice, but this treatment had negligible effects in the SF3B1 WT PDX recipients (Fig. 2d-g and Supplementary Fig. 5a-c) . Analysis of human leukemic cells purified from the mice 3 h after the last dose of H3B-8800 revealed reduced mature mRNA levels and accumulation of pre-mRNA resulting from canonical splicing events in all H3B-8800-treated mice, regardless of SF3B1 genotype. In contrast, reduced levels of aberrant splicing events induced by a mutation in SF3B1 were observed only in the SF3B1-mutant model ( Fig. 2h and Supplementary Fig. 5d ).
Given the activity and preferential efficacy of H3B-8800 on SF3B1-mutant human AML xenografts in vivo, we next tested H3B-8800 in mouse models with mutated SRSF2. After observing clear antitumor activity of H3B-8800 in mice bearing xenografts comprising SRSF2 P95H K052 cells (Supplementary Fig. 3b) , we generated six PDX models derived from patients with CMML, three of whom harbored SRSF2 mutations (Supplementary Table 2 ). A PDX model from each patient was generated, and the models were randomized to receive vehicle or H3B-8800 (8 mg/kg orally for 10 d) once human CD45 (hCD45) + cells in the peripheral blood made up >3% of total mononuclear cells or the concentration of hemoglobin was ≤11 g/dl (Fig. 3a) . Of note, leukemic burden was equivalent in mice bearing SRSF2 P95H tumors and those with SRSF2 WT tumors at the onset of treatment (Supplementary Fig. 6a ). H3B-8800 treatment reduced human leukemic burden in peripheral blood and all organs examined in PDX models with SRSF2 P95H but not in those with SRSF2 WT (Fig. 3b-h and Supplementary Figs. 6b and 7) . Moreover, we observed splenomegaly and hepatomegaly due to leukemic cell infiltration, and H3B-8800 treatment for 10 d substantially reduced spleen and liver size only in the SRSF2 P95H PDX models (Fig. 3d,e) . In accordance with the reduced number of mature leukemic cells observed in H3B-8800-treated PDX models of CMML bearing a mutant spliceosome, but not in those with a WT spliceosome, H3B-8800 treatment reduced the number of immunophenotypically defined leukemia-initiating cells only in spliceosome-mutant PDX models of CMML ( Supplementary  Fig. 8 ). Evaluation of RNA splicing in hCD45 + cells 3 h after the last dose of vehicle or H3B-8800 revealed that in vivo H3B-8800 treatment modulated aberrant splicing mediated by mutant SRSF2 (Fig. 3i,j) . In addition, H3B-8800 treatment resulted in decreased levels of mature MBD4 mRNA and accumulation of MBD4 pre-mRNA (Fig. 3j) as noted for the cell lines treated with H3B-8800 (Fig. 1f) . These data further suggest the efficacy and preferential activity H3B-8800 in treating spliceosome-mutant malignancy in vivo.
To further understand the preferential effects of H3B-8800 on spliceosome-mutant cells, we performed RNA-seq analysis of isogenic SF3B1 WT and SF3B1 K700E K562 cells treated with DMSO or H3B-8800. We observed enrichment of alternative 3′ splice sites in DMSO-treated K562 SF3B1 K700E cells as compared to DMSOtreated SF3B1 WT cells ( Supplementary Fig. 9a and Supplementary  Table 3) , consistent with prior reports on the effects of SF3B1 mutations on splicing 17, 18 . At a concentration of 13 nM, the half-maximal inhibitory concentration (IC 50 ) of H3B-8800 in a cell viability assay at 72 h following treatment (Supplementary Fig. 1f ), H3B-8800 treatment for 6 h primarily induced exon-skipping and intron-retention events in K562 cells expressing SF3B1-K700E as compared to untreated (DMSO control) cells ( Supplementary Fig. 9c and Supplementary Table 3) . Genes in which splicing events in these categories occurred (n = 4,353) were more likely to show downregulated expression following H3B-8800 treatment as compared to DMSO treatment (P = 2.1 × 10 −26 , binomial proportion test; Supplementary Fig. 9d ,e and Supplementary Table 4 ). Expression of genes with intron-retention events that were predicted to induce degradation through the nonsense-mediated decay (NMD) pathway were further downregulated as compared tol e t t e r S genes with other types of intron-retention events (P = 6.37 × 10 −22 , Kruskal-Wallis H test; Supplementary Fig. 9h ). Notably, when we compared the effects of treatment with 13 nM H3B-8800 in K562 cells with SF3B1 K700E and in those with SF3B1 WT , we observed few effects on alternative 3′ splice site usage but a clear increase in exon-skipping and intron-retention events; however, the magnitude of these changes was minimal overall (75th quartile < (2 × log 2 (fold change)); Supplementary Fig. 9b and Supplementary Table 4 All P values were calculated using a two-tailed Student's t test.
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Considering that H3B-8800 has preferential cytotoxic effects on spliceosome-mutant cells as compared to spliceosome-WT cells despite similar overall effects on splicing as observed in the RNA-seq analysis, we next sought to understand the effects of H3B-8800 on splicing in more detail. Characterization of introns retained in K562 SF3B1 K700E cells following treatment with H3B-8800 revealed that 27.2% of all significantly retained introns (q < 0.05) were short (≤300 nt) and GC rich (≥60% GC content) relative to 6.1% in all genes with detectable spliced introns (P = 2.2 × 10 −16 ; Fisher's exact test; Fig. 4a) . A similar preferential retention of short, GC-rich introns was also seen following H3B-8800 treatment of NALM-6 SF3B1 K700E cells, an effect that was much less evident for E7107 treatment at a similar concentration (Supplementary Fig. 9f) . A recent report suggested that short, GC-rich introns represent a specialized class of introns characterized by minimal differences in GC content between the intron and the following exon 24 . We therefore examined these features in introns retained by H3B-8800 versus all introns from expressed genes. In the results from this analysis, introns retained after H3B-880 treatment were enriched for GC content along their length, and there was an equal enrichment for GC content along the length of the following exon, with local enrichment in GC content at the 5′ and 3′ splice sites (Fig. 4b) . The largest divergence in GC content from all genes with detectable spliced introns occurred at the 3′ splice site, where the U2AF2-binding Py-tract is found 25 26 (left) and only those branchpoints within introns retained in in K562 SF3B1 K700E cells following H3B-8800 treatment (right). (e) Top, depiction of two Ad2-derived pre-MRNA substrates: Ad2.14, in which the Py-tract contains five cytosines and five thymines, and Ad2.17, which also contains an alteration in the BPS to reduce binding affinity to U2 snRNP. The branchpoint nucleotide is labelled in red, and the nucleotide that was changed between Ad2.14 and Ad2.17 to alter branchpoint strength is bolded. Bottom, the results from in vitro splicing using these two pre-mRNA substrates. The y axis represents the percent response relative to DMSO control (0%). Data are represented as mean ± s.d.; n = 3 technical replicates. (f) Sashimi plot representing the average read density of three technical replicates in introns 3 and 4 of U2AF2 (top) and introns 20, 21, and 22 of RBM10 (below) of RNA-seq samples from K562 SF3B1 K700E cells treated with DMSO or H3B-8800. Exons are shown in black, and introns are shown in blue (DMSO treated) or red (H3B-8800 treated). Relative GC content (derived using a 100-bp sliding window) is depicted in a heat map below the reference sequence. (g) The effect of an increasing concentration of H3B-8800 on the level of U2AF2 pre-mRNA (black squares) and mature mRNA (open squares) in K562 SF3B1 K700E cells as quantified by qPCR. Data are represented as mean ± s.e.m.; n = 3 technical replicates. (h) Western blot analysis of U2AF2, SRPK1, and MCL1 protein levels following treatment of K562 SF3B1 K700E cells with H3B-8800 or E7107 at the indicated concentrations. β-actin and GAPDH were used as loading controls. the Py-tract of introns retained by H3B-8800 might be predominantly cytosine-rich although it was expected to be thymine-rich; we confirmed this inference via sequence motif analysis (Fig. 4c) . In contrast, introns retained by E7107 treatment were less GC-rich than those retained by H3B-8800, and they demonstrated a clear increase in GC content in the following exon (Supplementary Fig. 9g ).
As the 3′ region of the intron also contains the BPS, we next explored whether the BPS in introns retained following H3B-8800 treatment might also be GC rich. Using branchpoint location data from deep sequencing of K562 cells in Mercer et al. 26 , we discovered that, within introns retained by H3B-8800, the branchpoint nucleotide was less likely to be the preferred adenosine (68.8% versus 78.7%; P = 4.32 × 10 −9 ; Fisher's exact test; Fig. 4d ). This result strongly suggests that the BPS might play a role in determining which introns are more likely to be retained following H3B-8800 treatment. To test this hypothesis, we designed two substrates, Ad2.14 and Ad2.17, based on the Ad2 construct 27 ; both contain a partially cytosine-rich Py-tract conforming to the observed 3′ splice site sequence motif (Fig. 4e) . In addition, a base substitution in the BPS of in Ad2.17 was created to reduce binding fidelity to the U2 snRNP. Using these constructs, we observed that H3B-8800 exhibited a greater modulation of splicing for Ad2.17, the substrate with a weakened BPS (Fig. 4e) , suggesting that H3B-8800 selectively modulates splicing of introns with a GC-rich 3′ splice site and a weak BPS. In contrast, in the same experiment, E7107 showed a much smaller shift in IC 50 values (Supplementary Fig. 10a) . Results from similar experiments using two other sets of Ad2 constructs, each with identical pairs of weak and strong BPS sequences but with differing 3′ splice sites, revealed selective modulation by H3B-8800 of the construct with a weakened BPS in sequences with a Py-tract composed completely of cytosine (Supplementary Fig. 10c ) or with a partially cytosine-rich Py-tract that was dissimilar to the observed 3′ splice site sequence motif (Supplementary Fig. 10e ). In contrast, E7107 inhibited splicing of both sets of constructs equally (Supplementary Fig. 10b,d) . Moreover, in constructs in which the BPS was changed to increase fidelity for binding with the U2 snRNP, E7107 showed potent splicing inhibition (IC 50 , 8.8 nM), whereas H3B-8800 showed no inhibition ( Supplementary Fig. 11a,b) . Taken together, these results demonstrate that H3B-8800 exhibits sequence-specific properties that modulate splicing that are distinct from those of E7107.
To test whether genes containing short, GC-rich introns retained following H3B-8800 treatment are involved in pathways that might explain the preferential killing of spliceosome-mutant cells exhibited by the drug, we performed pathway enrichment analysis of genes whose splicing was affected by H3B-8800 treatment in the K562 isogenic cell lines. Pathways involved in mRNA splicing were among those significantly enriched for such genes (Supplementary Table 5 ). Considering the prior data showing that WT spliceosome components are necessary for the survival of spliceosome-mutant cells [7] [8] [9] [10] [11] , we focused on the disruption of mRNA splicing as a possible mechanism underlying the preferential lethality of H3B-8800 against spliceosome-mutant cells. First, we curated a complete list of genes encoding spliceosome components using information from several studies [28] [29] [30] (Supplementary Table 6 and Online Methods). Short, GC-rich introns retained by H3B-8800 were present in 41 of 404 genes encoding proteins in spliceosome complexes (P = 0.017; binomial proportion test; Supplementary Fig. 11c ), including genes encoding RNA binding motif protein 10 (RBM10) and the essential splicing factor U2AF2 (Fig. 4f and Supplementary Fig. 11d,f) . H3B-8800 treatment induced intron retention of U2AF2 in a dose-dependent manner (Fig. 4g) , indicating that H3B-8800 directly modulated the splicing of genes encoding proteins required for splicing catalysis, and this modulation resulted in a corresponding loss of U2AF2 protein expression in K562 cells (Fig. 4h) . Despite the effects of H3B-8800 on U2AF2 splicing and expression, stable reintroduction of full-length U2AF2 cDNA was unable to rescue H3B-8800-induced cell death (Supplementary Fig. 12 ), likely because H3B-8800 treatment affects expression of many additional splicing factors. For example, H3B-8800 treatment also induced a dose-dependent reduction in protein expression of SRPK1, a kinase involved in splicing factor regulation. Although both H3B-8800 and E7107 treatment reduced U2AF2 and SRPK1 protein expression, only E7107 treatment induced intron retention of MCL1 and reduced MCL1 protein expression (Fig. 4h  and Supplementary Fig. 13 ), further indicating that E7107 has a more pleiotropic effect on splicing modulation than H3B-8800.
The data presented here identify H3B-8800 as a small molecule that selectively modulates splicing to induce preferential lethality in cancer cells bearing a mutant spliceosome. Recent work has shown that short, GC-rich introns are recognized by an intron-defined splicing mechanism that is associated with intron retention observed in cells under normal conditions 24 . We demonstrate that H3B-8800 preferentially induces retention of these introns, which are characterized by short length, high GC content, and low differentiation in GC content compared with the following exon. Together, these findings suggest that H3B-8800 treatment selectively modulates a pre-existing mechanism for splicing recognition, and this selectivity is not shared with other small-molecule modulators of splicing. The enrichment for intron retention in mRNAs encoding RNA splicing factors provides an explanation for H3B-8800's preferential killing of spliceosome-mutant tumor cells, which are already deficient in splicing, as compared to spliceosome-WT cells. As the expression of numerous RNA splicing factors was influenced by H3B-8800 treatment, the killing effects of the drug are not attributable to altered expression of any single target.
Despite the fact that the global alterations in splicing conferred by mutant SF3B1 (refs. 17,18) , SRSF2 (refs. 15, 19) , and U2AF1 (ref. 16) are distinct from one another, cells bearing any of the corresponding mutations have been shown to exhibit dependency on the remaining WT spliceosome [7] [8] [9] [10] [11] . It is therefore predicted that expression of any of these cancer-associated RNA splicing factor mutations would confer sensitivity to H3B-8800. The preferential vulnerability of SRSF2-and SF3B1-mutant cells to H3B-8800 results in the differential lethality observed in vitro and in vivo. The selective mechanism of action of H3B-8800 in combination with its unique pharmacological profile among previously described direct modulators of splicing supports clinical testing of H3B-8800 in genetically defined subsets of cancer with RNA splicing factor mutations.
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Cell culture. The cell lines HCT-116, Panc05.04, Panc10.05, HPAF-II, CFPAC1, and Panc04.03 were obtained from the American Type Culture Collection (ATCC) or from RIKEN BioResource Center and cultured as instructed. The isogenic paired cell lines (K562 and NALM-6 SF3B1 K700E and SF3B1 WT ) were generated at Horizon Discovery and were cultured in the presence of Geneticin (0.7 mg/ml, Life Technologies) for selection. HCT116 clones resistant to H3B-8800 were generated by treating cells with 4 nM of splicing modulator for 2 weeks. Splicing modulator was refreshed every 4 d. When needed, confluent cells were split in a 1:3 ratio and were allowed to recover overnight without splicing modulator treatment after reseeding. At the end of the 2 weeks of compound selection, individual clones were transferred to 12-well plates and further expanded without splicing modulator. Genomic DNA was extracted using the DNeasy Blood & Tissue Kit from Qiagen. The resistance mutations SF3B1 R1074H and PHF5A Y36C were identified by whole exome sequencing.
Cell viability and apoptosis assays. Pancreatic cancer cells were seeded at 750 cells per well in a 384 well plate and treated with compound on day 2. K562 isogenic cells (K562-SF3B1 K700E and K562-SF3B1 K700K ) were seeded at 10,000 cells per well in 96-well plates and treated with compound 4 h later. The relative numbers of viable and apoptotic cells were measured via luminescence using CellTiter-Glo or Caspase-Glo 3/7 (Promega) at the indicated time points as instructed. Bortezomib was obtained from Selleckchem.
Expression plasmids. The plasmids used in the scintillation proximity assay were generated through cloning the cDNA of mxSF3B1 (cloned by ligating the N-terminal half of the product of the mouse Sf3b1 open reading frame (ORF) and the C-terminal half of the product of the Xenopus Sf3b1 ORF, followed by replacement of three amino acid residues in the product of the Xenopus ORF with three human amino acid residues) into the HindIII and KpnI sites of pFlag-CMV2 (Sigma). The mutations corresponding to mxSF3B1-E622D, mxSF3B1-R625L, mxSF3B1-H662Q, mxSF3B1-K666E, mxSF3B1-K666N, mxSF3B1-K666R, mxSF3B1-K700E, and mxSF3B1-G742D were introduced using a site-directed mutagenesis kit (QuikChange II XL, Agilent). Mammalian U2AF2 expression plasmids were generated using Gateway cloning technology (Life Technologies). N-terminal hemagglutinin (HA)-tagged U2AF2 (NP_ 009210.1) was cloned into the pLenti6.3-V5 Dest vector (Life Technologies), which was used to transfect LentiX293 cells (Promega). Viral supernatants from these cells were then used to infect K562 isogenic cells. These isogenic K562 cells were selected for construct expression using 4 µg/ml blasticidin.
Nuclear extract preparation. Nuclear extracts were prepared from either HeLaS3 or 293F cells expressing pFLAG-mxSF3B1 plasmids, 293FT cells expressing mxSF3B1, or HCT116 cells. Expression of mxSF3B1 was achieved in 293F cells by transfecting pFLAG-CMV-2-mxSF3B1 plasmids using Lipofectamine 2000 (Life Technologies) and in 293FT cells using the PiggyBac transposon system. Cell pellets were resuspended in hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and 0.5 mM dithiothreitol (DTT)). The suspension was brought up to a total of 5 packed cell volumes (PCV). After centrifugation (3,000 r.p.m. for 5 min at 4 °C), the supernatant was discarded, and the cells were brought up to 3 PCV with hypotonic buffer and incubated on ice for 10 min. Cells were lysed using a dounce homogenizer and then centrifuged (4,000 r.p.m. for 15 min at 4 °C). The supernatant was discarded, and the pellet was resuspended with ½ packed nuclear volume (PNV) of low-salt buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 20 mM KCl, 0.2 mM EDTA, 25% glycerol, 0.2 mM PMSF, 0.5 mM DTT), followed by ½ PNV of high-salt buffer (same as low salt buffer except 1.4M KCl was used). The nuclei were gently mixed by rotating for 30 min before centrifuging (10,000 r.p.m. for 30 min at 4 °C). The supernatant (nuclear extract) was then dialyzed into storage buffer (20 mM HEPES pH 7.9, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.2 mM PMSF, 0.5 mM DTT). Protein concentration was determined using a NanoDrop 8000 UV-Vis spectrophotometer (Thermo Scientific).
In vitro splicing reaction. The Ad2-derived 31 sequence was cloned into the pGEM-3Z vector (Promega) using 5′ EcoRI and 3′ XbaI restriction sites. The Ad2 variants (Ad2.12-Ad2.17; all modifications are described in Fig. 4e and Supplementary Fig. 10 ) were cloned into the pcDNA3.1(+) vector (Promega) using the same restriction sites. The Ad2-ZDHHC16 hybrid substrate, which contained exons from the Ad2 vector and intron 9 from ZDHHC16, was cloned into the pcDNA3.1(+) vector using the same restriction sites. The plasmids were linearized using XbaI and then were used as DNA templates in the in vitro transcription reactions. The Ftz plasmid that lacked introns (Ftz∆i) was obtained from Luo & Reed 32 and linearized using EcoRI. All RNAs were in vitro transcribed using the MEGAScript T7 kit and then purified using the MegaClear kit (Invitrogen).
For splicing reactions using pre-mRNAs of Ad2 variants, reactions were prepared using 8 µg of HeLa S3 nuclear extract, 2 ng pre-mRNA, 0.2 ng control, and varying concentrations of H3B-8800, E7107, or DMSO to reach a final reaction volume of 1 µl in this high-throughput assay. After a 15-min preincubation at 30 °C, 1 µl of splicing-activation buffer (0.5 mM ATP, 20 mM creatine phosphate, 1.6 mM MgCl 2 ) was added, and the reactions were incubated for 90 min at 30 °C. The reactions were then quenched with 13 µl DMSO, and 25 nl was used for RT-qPCR.
For splicing reactions using pre-mRNA of the Ad2-ZDHHC16 hybrid, 1 µl reactions were prepared using 10 µg nuclear of extract prepared from 293FT PiggyBac cells, 8 ng pre-mRNA, and varying concentrations of H3B-8800, E7107, or DMSO. After a 15-min preincubation at 30 °C, 2 µl splicing-activation buffer was added, and the reactions were incubated for 90 min at 30 °C. RNA was extracted using a modified protocol from a RNeasy 96 Kit (Qiagen). The splicing reactions were quenched in 350 µl Buffer RLT Plus (Qiagen), and 1.5 volume of ethanol (555 µl) was added. 100 nl of quenched splicing reactions was used for RT-qPCR.
RT-qPCR reactions were prepared using the TaqMan RNA-to-C T 1-step kit (Life Technologies), RNA from splicing reactions, Ad2 canonical junction (forward: 5′-ACTCTCTTCCGCATCGCTGT-3′; reverse: 5′-CCGACGGGTTTCCGATCCAA-3′; probe: 5′-CTGTTGGGCTCGCGGTTG-3′) or Ad2 aberrant junction (probe: 5′-CCAGCTGTTGGGTCTTCGCCC-3′) and Ftz (forward: 5′-TGGCATCAGATTGCAAAGAC-3′; reverse: 5′-ACGCCGGGTGATGTATCTAT-3′; probe: 5′-CGAAACGCACCCGTCAGACG-3′) mRNA primer-probe sets.
Competitive binding assay. SF3B complexes were immunoprecipitated from nuclear extracts prepared from 293F cells overexpressing Flag-tagged SF3B1. First, batch immobilization of antibody to beads was performed through incubating 80 µg of anti-SF3B1 antibody (MBL International D221-3, Anti-Sap155 monoclonal antibody) and 24 mg anti-mouse PVT scintillation proximity assay (SPA) beads (PerkinElmer) for 30 min. After centrifugation (14,000 r.p.m. for 5 min at 4 °C), the antibody-bead mixture was resuspended in PBS supplemented with PhosSTOP phosphatase inhibitor cocktail (Roche) and cOmplete ULTRA protease inhibitor cocktail (Roche). Nuclear extracts were prepared through diluting 40 mg into a total volume of 16 ml PBS with phosphatase and protease inhibitors, and the mixture was centrifuged (14,000 r.p.m. for 10 min at 4 °C). The supernatant was transferred into a clean tube, and the antibody-bead mixture was added and incubated for 2 h. The beads were collected via centrifuging, washed twice with PBS + 0.1% Triton X-100, and resuspended with 4.8 ml of PBS. 100 µl binding reactions were prepared using slurry and varying concentrations of H3B-8800. After 15 min preincubation at room temperature, 1 nM 3 H-probe used in Kotake et al. 20 was added. The mixture was incubated at room temperature for 15 min, and luminescence signals were read using a MicroBeta2 Plate Counter (PerkinElmer).
RNA-seq sample preparation. NALM-6 and K562 isogenic cell lines were treated with H3B-8800 or E7107 at the indicated doses (in Fig. 4 ) for 6 h. After treatment, the cells were washed with PBS, and RNA was isolated using PureLink (Life Technology) according to the manufacturer's instructions. cDNA library preparation, sequencing, and raw read filtering methods were described previously 17 .
U2 snRNP complex assembly assay. This assay was performed as previously described by Folco 23 . The BBR 2′-O-methyl oligonucleotide complementary to the branch point binding region (5′-mCmAmGmAmUmAmCmUmAmAmCmAmCmUmUmGmA-3′) and the control oligonucleotide (5′-mAmCmUmGmGmCmAmGmCmAmAmUmGmAmCmUmG-3′) were 32 P-labeled using γ-ATP (6,000 Ci/mmol, Perkin Elmer) and T4 polynucleotide kinase. For all assays, ATP was depleted from nuclear extracts through incubation for 20 min at room temperature. Reaction mixtures (25 µl) containing the depleted nuclear extract (15 µl) were preincubated with or without 1 µM H3B-8800 for 5 min at 30 °C, followed by incubation with 0.5 mM ATP, 3.2 mM MgCl 2 , and 20 mM creatine phosphate (di-Tris salt) for 5 min at 30 °C. For reactions carried out in the absence of ATP, water was used to supplement the reaction mixture. The radiolabeled BBR or control 2′-O-methyl oligonucleotide (30 ng of each) was added to the reaction mixture last, and the reaction mixture was incubated for 5 min at 30 °C. G50 columns (GE Healthcare) were used to purify the samples before adding 6× DNA loading dye and running 1.2% native low-melting agarose (Invitrogen) gels in Tris/borate/EDTA (TBE) buffer at 70 V for 2 h at room temperature to resolve the 17S and 12S U2 snRNPs. Gels were dried, exposed overnight to a PhosphorImager screen, and imaged.
Real time qPCR and RT-PCR. RNA was extracted from K562 cells using PureLink (Life Technology) according to the manufacturer's instructions. cDNA was synthesized using the SuperScript VILO II (Life Technologies) according to the manufacturer's instructions. cDNA was diluted to 20 ng input for qPCR using the Viia7 system (Life Technologies). For detection of U2AF2 mature mRNA, the following primer-probe set was used: forward: 5′-GAGCACGGTGGACTGATTC-3′; reverse: 5′-GGTGATGTGCTCAAAGCCT-3′; and probe: 5′-CCGCCACGAGAAGAAGAAGAAGGT-3′. For detection of U2AF2 pre-mRNA, the following primer-probe set was used: forward: 5′-TGTTGGTCAGACTGAGGTTG-3′; reverse: 5′-GTGGCACGTCCCAGT ATTTA-3′; and probe: 5′-CCGCCACGAGAAGAAGAAGAAGGT-3′.
RNA was extracted from patient material and PDX models and was used to generate cDNA as previously described 11 . RT-PCR analyses for expression of EZH2 and GAPDH were also performed using methods and primers as previously described 11 . For detection of the CEP57 aberrant junction, the following primer-probe set was used: forward: 5′-TGCAGACTGGTCTAGAAACAAA-3′; reverse: 5′-GCTAGGGCTTGTGGACTTT-3′; and probe: 5′-ACTCCGTG TGTTCCCAATGCAAGA-3′. Statistical comparison of the expression of mRNA isoforms as determined through qPCR data was performed using the Student's t-test.
TaqMan low-density arrays. K562 isogenic cell lines were seeded at 1 × 10 5 cells per well in 96-well plates, and Panc05.04 and Panc10.05 cells were seeded at 1.5 × 10 4 cells per well in a 96-well plate and treated with various concentrations of H3B-8800 for 6 h. RNA (0.5 µg for in vitro studies and 2 µg for in vivo studies) was reverse transcribed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, CA, USA) following the standard protocol. The resulting cDNA was diluted, and the equivalent of 100 ng was used to prepare a sample specific PCR mix by combining with 50 µl TaqMan Gene Expression Master Mix (Thermo Fisher Scientific, CA, USA) and water up to a final volume of 100 µl. The PCR mix was loaded into the sample fill port of a 24-gene custom developed TaqMan Low-Density Array Card (Thermo Fisher Scientific, CA, USA), which contained two printed technical replicates of each assay per fill port. The TLDA was loaded with eight individual samples and prepared and run on the ViiA7 Real-Time PCR system following the manufacturer's recommendations (Thermo Fisher Scientific, CA, USA). Threshold PCR cycle (Ct) was determined by the ViiA7 RUO software v 1.2.3 (Thermo Fisher Scientific, CA, USA) using a relative threshold. A Ct greater than or equal to 35 was considered undetectable. Two technical replicates were averaged, and the geometric mean of the expression of five housekeeping genes (B2M, EEF1A1, GAPDH, RPLP0, TUBB) was calculated and used to normalize data as the first step in the comparative ∆∆Ct method followed for analysis. Data shown represent three experimental replicates. The list of primers and probes included in the TLDA are reported in Supplementary Table 7. K562 isogenic lines, HNT-34 and K052 xenograft models efficacy and pharmacokinetic/pharmacodynamic modeling. 1 × 10 7 K562 isogenic, HNT-34, or K052 cells were subcutaneously implanted into the flank of female NSG or CB17-SCID mice of 6-8 weeks of age. Mice were treated with H3B-8800 (10% ethanol, 5% Tween-80, 85% saline) or vehicle control. For the efficacy studies, the mice were orally dosed daily, and the mice were monitored until they reached either of the following endpoints: (i) excessive tumor volume (≥20 mm in its longest diameter), which was measured three times a week (tumor volume calculated by using the ellipsoid formula: (length × width2) / 2), or (ii) development of any health problem, such as paralysis or excessive body weight loss. The differences in tumor volume during the study period between the vehicle-treated and H3B-8800-treated groups were analyzed by two-way analysis of variance (ANOVA) followed by the Dunnett's multiple comparison test. For the pharmacokinetic/pharmacodynamic modeling (PK/PD) studies, the mice were treated with one dose, and the tumors were collected at the indicated times (in Figs. 2 and 3) after treatment for further analysis. RNA was isolated using RiboPure RNA purification kit (Ambion) and used for TLDA. All mouse studies were carried out under protocols approved by the Institutional Animal Care and Use Committee at H3 Biomedicine. Generation of PDX models. Generation of CMML PDX models was performed as described in detail by Yoshimi et al. 33 . Briefly, 6-to 10-week-old NSGS (stock no. 013062) female mice were purchased from the Jackson Laboratory and sublethally irradiated (200 cGy) 3-24 h before transplantation followed by direct intrafemoral injection. CD34 + cells were purified from viably frozen patient bone marrow mononuclear cells (MNCs) through immunomagnetic selection (Miltenyi Biotec). CBC analysis was performed on peripheral blood collected from submandibular bleeding or cardiac puncture post-euthanasia using a Procyte Dx Hematology Analyzer (IDEXX Veterinary Diagnostics). Each of the CMML PDX models used has been previously described 33 . Genomic analysis of patient bone marrow MNCs and FACS-purified hCD45 + cells from corresponding xenografts was performed using a targeted next-generation sequencing assay as previously described 34 .
AML PDX models were generated as previously described 11 , with the exception that NSGS mice were used as recipients (as was done for CMML PDX models described above). All mouse studies were carried out according to the MSKCC Guide for the Care and Use of Laboratory Animals.
Flow cytometric analysis of PDX models. All flow cytometric antibodies (for both human and mouse studies) were purchased from BD Pharmingen, Biolegend, or eBioscience. Mononuclear cells (MNCs) from patient samples, xenografted tissues, or PB were stained with a combination of antibodies against human CD3 (hCD3, clone: OKT3, purchased from eBioscience), hCD14 (61D3, eBioscience), hCD16 (3G8, Biolegend), hCD19 (HIB19, eBioscience), hCD33 (WM-53, eBioscience), hCD34 (4H11, eBioscience), hCD38 (HB-7, Biolegend), hCD45 (2D1, eBioscience), hCD45RA (HI100, Biolegend), hCD90 (5E10, Biolegend), and hCD123 (7G3, BD Bioscience). Antibodies against mouse CD45.1 (A20, eBioscience) and Ter119 (catalog no. 116223, Biolegend) were used to exclude host-derived cells.
Quantification of RNA-seq data. Raw sequence reads were aligned to the human reference sequence hg19 by STAR 2.4.2a using two-pass alignment 35 , and isoform quantification was performed using Kallisto 0.42. 4 
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